Why did Yamasa, a soy sauce maker founded in 1645, end up in pharmaceuticals? The story of how umami research led to nucleotides, and to pseudouridine, a key ingredient in mRNA vaccines.
In 2004, virologist Yoshihiro Kawaoka titled a dialogue A Pandemic Will Definitely Come. COVID proved him right 16 years later, and the bird flu he truly feared, H5N1, is now spreading in cattle and people. A 20-year reckoning.
Researchers at the University of Tokyo and Chiba University have developed ETE, a method that mass-produces hundreds of thousands of uniform cell-loaded capsules using only a bench-top vortex mixer and temperature control. A look at why it lowers the barrier for drug discovery and regenerative medicine, and how it compares with America's organoid industry.
A meniscus regeneration technology developed at Japan's Institute of Science Tokyo has been approved as Seibiscus, the country's first regenerative medicine product for meniscus injury. We explain how it uses a patient's own stem cells to repair the knee, what the Phase III trial showed, and how it compares with regenerative medicine ventures in South Korea and the US.
Kyoto University spinout Toregem Biopharma will begin Phase 2 trials of TRG035, the world's first tooth-regeneration drug, in summer 2026, dosing 24 children with congenital tooth agenesis. A pre-Series C round of ¥850 million brings cumulative funding, grants included, past ¥4.6 billion. A look at how Japan's university-biotech funding stack works, and why a super-aged society may produce this kind of innovation first.
After a stroke, the brain repairs itself for about two months, then stops. A team from Science Tokyo, TMIMS, Kyushu University and Freiburg University has identified the protein responsible, ZFP384, and developed an antisense drug that keeps the repair window open in mice. Published in Nature, the discovery could redraw what is possible for stroke survivors and other brain injuries.
On May 20, 2026, Japan added three ultra-expensive regenerative medicines to public insurance coverage: Amshepri (world's first iPS cell-derived drug, for Parkinson's), Akugo (stem cells for traumatic brain injury), and Zolgensma Intrathecal (gene therapy for SMA patients aged 2+). Prices range from 55 million yen ($352K) to 167 million yen ($1.06M). We explain why these drugs cost so much, how Japan's high-cost medical expense system shields patients, and whether prices might fall over time.
A Japanese research team led by Gakushuin University has discovered Mitorubin, a plant-derived compound that simultaneously increases mitochondrial quantity and function. The compound improved heart function in aged mice and extended median lifespan by about 40% in obese mice on a high-fat diet — a distinct approach from US longevity biotech, NAD supplements, and senolytics.
A Japanese team led by Prof. Takanori Takebe (Osaka & Science Tokyo) and Dr. Mureo Kasahara (National Center for Child Health and Development) plans the world's first pediatric clinical trial of UTOpiA, a bioartificial liver that perfuses blood through iPS-derived liver organoids. Animal trials showed 90% survival. How it compares with King's College London's HELP trial and Beijing's CiPS-BAL.
Researcher Yohei Kawai and Professor Shin Kaneko at Kyoto University's CiRA have established a way to induce helper T cells, the conductors of the immune system, from human iPS cells without mouse feeder cells. The paper ran in Molecular Therapy on January 20, 2026. Why this matters against the three structural limits of CAR-T therapy, and where Japan stands against Fate Therapeutics in the US and China's sheer trial volume.
A Tohoku University-UC Irvine team led by Prof. Kei Igarashi has discovered that dopamine in the entorhinal cortex drops to less than one-fifth of normal levels in Alzheimer's mice, driving memory loss. Published in Nature Neuroscience, the finding suggests Levodopa—a Parkinson's drug used for over half a century—could restore memory in Alzheimer's, opening a new path beyond the amyloid-beta hypothesis behind drugs like lecanemab.